Cited by 284Pharmaceutical Economics and PolicyPharmaceutical industry and healthcareAlzheimer's disease research and treatments

The DOI matches its Crossref record.

Is Pharma Running Out of Brainy Ideas?

Miller, Greg·2010·Science

DOI 10.1126/science.329.5991.502

Open this paper in CoChat — free account

Abstract

Recent cutbacks raise concerns about the future of drug development for nervous system disorders.

Integrity signals

Registry

Crossref · 10.1126/science.329.5991.502

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Sorted by citations

Items 201–283 of 283

Architecting Discovery: A Model for How Engineers Can Help Invent Tools for Neuroscience
Boyden, E. S., & Marblestone, A. H. (2019) · Neuron · doi:10.1016/j.neuron.2019.03.023 · Cited by 2
“In addition, treatments for brain diseases remain relatively few; brain drugs cost perhaps $1 billion each for clinical development, taking a decade for clinical approval, and even those that make it to human trials fail 90% of the time to be approved for human use (Miller, 2010).”
First‐in‐human development of a pharmacodynamic biomarker for PAC1 receptor antagonists using intradermal injections of maxadilan
Marynissen, H., Buntinx, L., Bamps, D., et al. (2022) · Clinical and Translational Science · doi:10.1111/cts.13309 · Cited by 2
Finding the pathology of major depression through effects on gene interaction networks
Gaiteri, C. (2011) · D-Scholarship@Pitt (University of Pittsburgh) · Cited by 2
Editorial (Thematic Selection: Inflammatory and Immune Responses in Depression)
Sharma, A. (2016) · Current Neuropharmacology · doi:10.2174/1570159x1407160826191654 · Cited by 2
“In stark contrast to revolutionary, mostly serendipitous, discovery of psychiatric drugs between the end of 1940's and late 1950's, followed by a period of stagnancy during the next half a century, the last decade has witnessed drug development pipeline for nervous system disorders drying up, and major pharmaceutical…”
Background
Venture Capital Response to Government-Funded Basic SciencePreprint
Rezaei, R., & Yao, Y. (2024) · Social Science Research Network · doi:10.2139/ssrn.5044008 · Cited by 2
Psilocin fosters neuroplasticity in iPSC-derived human cortical neuronsPreprint
Schmidt, M., Hoffrichter, A., Davoudi, M., Horschitz, S., Lau, T., Meinhardt, M. W., Spanagel, R., Ladewig, J., Köhr, G., & Koch, P. (2025) · eLife · doi:10.7554/elife.104006.1 · Cited by 2
A Paradigm Shift from DSM-5 to Research Domain Criteria: Application to Translational CNS Drug Development
Potter, W. Z., & Cuthbert, B. N. (2021) · Springer eBooks · doi:10.1007/978-3-030-62351-7_14 · Cited by 1
A Paradigm Shift from DSM-5 to Research Domain Criteria: Application to Translational CNS Drug Development
Potter, W. Z., & Cuthbert, B. N. (2024) · Springer eBooks · doi:10.1007/978-3-031-61992-2_19 · Cited by 1
New Dawn of Edible and Medicinal Fungi Unlocking Central Nervous System Diseases
Liu, X., Zhang, G., & Ling, J. (2025) · Journal of Food Science · doi:10.1111/1750-3841.70230 · Cited by 1
Machine Learning-driven QSAR and Docking Pipeline for Identification of Amyloid Beta-A4 Inhibitors in Alzheimer’s Disease
Korlagunta, S. R., Selvan, I. M., & Dhanasekaran, S. (2026) · Journal of Pharmacology and Pharmacotherapeutics · doi:10.1177/0976500x261417108 · Cited by 2
“8 Amyloid-β (Aβ) plaque accumulation represents a pathological characteristic of AD, occurring 15–20 years prior to the onset of clinical symptoms.”
Two kinds of autism: a comparison of distinct understandings of psychiatric disease
Verhoeff, B. (2015) · Medicine Health Care and Philosophy · doi:10.1007/s11019-015-9655-4 · Cited by 2
1H-NMR spectroscopy for human 3D neural stem cell cultures metabolic profiling
Simão, D. F., Pinto, C., Teixeira, A. P., Alves, P. M., & Brito, C. (2013) · BMC Proceedings · doi:10.1186/1753-6561-7-s6-o8 · Cited by 1
“The current lack of predictable central nervous system (CNS) models in pharmaceutical industry early stage development strongly contributes for the high attrition rates registered for new therapeutics [1].”
Background
Institutional Profile: The Center for Biomarker Research and Personalized Medicine at Virginia Commonwealth University: Advancing Psychiatric Drug Treatment
McClay, J. L. (2012) · Personalized Medicine · doi:10.2217/pme.12.52 · Cited by 1
Antidepressants and Major Depressive Disorder
Stein, D. J. (2012) · doi:10.2217/9781780840284 · Cited by 1
Mental Health's Stalled (Biological) Revolution: Its Origins, Aftermath & Future Opportunities
Harrington, A. (2023) · Daedalus · doi:10.1162/daed_a_02037 · Cited by 1
“49 And then came one final blow.”
The human brain—from cells to society
Hoogland, E., Patten, I., & Berghmans, S. (2013) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2013.00359 · Cited by 1
“The number of new drugs entering the pipeline for the treatment of brain disorders, in particular mental illness, has declined dramatically (Miller, 2010).”
BackgroundInfluential
Medicating and Technologizing Our Diagnosable Lives
Strong, T. (2017) · Springer eBooks · doi:10.1007/978-3-319-56699-3_6 · Cited by 1
De ontstoken geest
Meijer, O. G., & Mahieu, Y. A. (2018) · Neuropraxis · doi:10.1007/s12474-018-00208-w · Cited by 1
Fármacos inovadores em saúde mental
de Macedo, J. B., Pereira, A. V., Perek, K. V., & Karas, L. P. (2018) · Revista de Medicina · doi:10.11606/issn.1679-9836.v97i4p385-395 · Cited by 1
The use of vitamin D in depression
Lange, K. W., Lange, K. M., Nakamura, Y., & Reißmann, A. (2021) · Journal of Food Bioactives · doi:10.31665/jfb.2021.15278 · Cited by 1
“The need for the development of further medications and novel approaches to the prevention and treatment of depression has therefore been emphasized (Insel, 2015; Miller, 2010).”
Background
Serotonin noradrenaline reuptake inhibitors
Bourin, M. (2012) · doi:10.2217/ebo.11.193 · Cited by 1
The Solution to Science's Replication CrisisPreprint
Knuteson, B. (2016) · SSRN Electronic Journal · doi:10.2139/ssrn.2835131 · Cited by 2
Noradrenergic and specific serotonergic antidepressants
Heck, E., & MacQUEEN, G. M. (2012) · doi:10.2217/ebo.11.227 · Cited by 3
EEG biomarkers in depression: paving the way for stratified psychiatry
van der Vinne, N. (2020) · doi:10.3990/1.9789083001333 · Cited by 1
Editorial: Biological Psychology in the rearview mirror—From the clinic to the clinic
Arns, M., Heinrich, H., & Olbrich, S. (2022) · Biological Psychology · doi:10.1016/j.biopsycho.2022.108263 · Cited by 1
“At that time psychopharmacology was still the predominant model for the treatment of mental health disorders, until in 2010 GlaxoSmithKline Chief Executive Andrew Witty announced a suspension of their R&D budgets for central nervous system disorders (more specifically psychiatry) (Miller, 2010).”
Background
Mouse brain-wide transgene expression by systemic injection of genetically engineered exosomes: CAP-ExosomesPreprint
Sarkar, S. N., Corbin, D. R., & Simpkins, J. W. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.04.06.487362 · Cited by 1
What has Happened to R&D Productivity?
LaMattina, J. L. (2012) · doi:10.1002/9781118511329.ch2
The discovery and development of drugs to treat psychiatric disorders: Historical perspective
Williams, M., & Barrett, J. E. (2012) · Cambridge University Press eBooks · doi:10.1017/cbo9780511980053.002
Improving success of novel therapeutics for cognitive aspects of psychiatric disease: a bridge too far?
Gastambide, F., & Gilmour, G. (2012) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.12.63
Biological Psychiatry: A Time of Opportunity, a Time of Challenge
Krystal, J. H. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.04.020
Next Generation Antidepressants. Moving Beyond Monoamines to Discover Novel Treatment Strategies for Mood Disorders. Edited by C. E. Beyer and S. M. Stahl. (Pp. 150; £50.00; ISBN 9780521760584 hb.) Cambridge University Press: Cambridge. 2010.
Walsh, N. (2010) · Psychological Medicine · doi:10.1017/s0033291710002266
Could Monitoring Methylation Markers Aid the Management of Schizophrenia?
Åberg, K. A., & van den Oord, E. J. C. G. (2014) · Biomarkers in Medicine · doi:10.2217/bmm.14.44
Functional modelling of cortical macro-networks: a dissertation submitted for the degree of Doctor of Philosophy
Bányai, M. (2013)
Topología molecular aplicada a la búsqueda de nuevos fármacos para el tratamiento de la epilepsia refractaria
Ianni, M. E. D. (2015) · doi:10.35537/10915/51575
Making Perfect Life
Geesink, I., van Keulen, I., Schuijff, M., Brom, F. W. A., & van Est, Q. C. (2009)
Which therapy for which patient?
Greer, T. L., Kurian, B. T., & Trivedi, M. H. (2012) · doi:10.2217/ebo.11.299
Screening of a Histone Methyltransferase Inhibitor in Animal Models of Psychiatric Illness
Kosowan, J. (2014) · TSpace (University of Toronto)
The Translational Umbrella - A Novel Approach to the Study of the Biological Basis of Mental Health
Ellenbroek, B. A., & Wang, W. (2018) · OBM Neurobiology · doi:10.21926/obm.neurobiol.1801008
Serotonin reuptake and receptor blockers
Ameringen, M. V., Patterson, B. A., & Lee, E. (2012) · doi:10.2217/ebo.11.324
Melatonin receptor agonists/5-HT2Cantagonists
Kennedy, S. H., & Rizvi, S. J. (2012) · doi:10.2217/ebo.11.291
Noradrenaline dopamine-reuptake inhibitors
Silverstone, P. H. (2012) · doi:10.2217/ebo.11.262
Optogenetics: Tools for Controlling Brain Cells with Light
Boyden, E. S. (2019) · Molecular Frontiers Journal · doi:10.1142/s2529732519400133
The Solution to Science's Replication CrisisPreprint
Knuteson, B. (2016) · RePEc: Research Papers in Economics · doi:10.48550/arxiv.1609.03223
Navigating the Novel Psychotropics
Dunlop, B. W. (2021) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20200044
Psychiatry between Psyche and Brain
Fuchs, T. A. E. (2021) · doi:10.1093/oso/9780192898197.003.0009
Intellectual Property and Policy Issues in Biotechnology
Yancey, A. (2011)
Generic
(2022) · Duke University Press eBooks · doi:10.1215/9781478022282-010
Relative Value
(2022) · Duke University Press eBooks · doi:10.1215/9781478022282-003
Embodied Value Theory
(2022) · Duke University Press eBooks · doi:10.1215/9781478022282-002
Culture, Context, and Consensus
(2022) · Duke University Press eBooks · doi:10.1215/9781478022282-009
Never Enough
(2022) · Duke University Press eBooks · doi:10.1215/9781478022282-004
What Drugs Do in Different Spaces
(2022) · Duke University Press eBooks · doi:10.1215/9781478022282-007
References
(2022) · Duke University Press eBooks · doi:10.1215/9781478022282-013
Failed Biocommensurations
(2022) · Duke University Press eBooks · doi:10.1215/9781478022282-012
Acting through Other (Prescribing) Habits
(2022) · Duke University Press eBooks · doi:10.1215/9781478022282-008
Making a Difference
(2022) · Duke University Press eBooks · doi:10.1215/9781478022282-005
Pharmaceutical Citizenship, Marketing, and the Global Monoculture of Health
(2022) · Duke University Press eBooks · doi:10.1215/9781478022282-006
The Translational Umbrella - A Novel Approach to the Study of the Biological Basis of Mental Health
Ellenbroek, B. A. (2018) · OBM Neurobiology · doi:10.21926/obm.neurobiology.1801008
The Apparent Declining Efficiency of Drug Discovery
Trist, D. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.02476-8
What are Fear and Anxiety? Listening to the Brain
LeDoux, J. E. (2017) · doi:10.1093/med/9780190681425.003.0036
PACITA: Book Proceedings from the PACITA 2013 Conference in Prague (Prague,--15 March 2013)
(2018) · doi:10.1553/ita-pacita-05
Index
(2012) · doi:10.2217/ebo.11.197
Critical Neuroscience and Mental Health
Strong, T. (2021) · Springer eBooks · doi:10.1007/978-3-030-12852-4_34-1 · Cited by 1
PACITA: Expert Working Group report for the European Future Panel on Public Health Genomics (January 2014)
(2018) · doi:10.1553/ita-pacita-06
The Nimh Research Domain Criteria Project
Cuthbert, B. N. (2017) · Oxford University Press eBooks · doi:10.1093/med/9780190681425.003.0071
Glutamatergic antidepressants
Kalra, H., Dean, O. M., Dodd, S., & Berk, M. (2012) · doi:10.2217/ebo.11.273
Corrections
(2015) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70300-x
Introduction
(2022) · Duke University Press eBooks · doi:10.1215/9781478022282-001
Same Ills, Same Pills
(2022) · Duke University Press eBooks · doi:10.1215/9781478022282-011
РЕНЕСАНС ПСИХОДЕЛІЧНОЇ ТЕРАПІЇ ТА ЇЇ ЗНАЧЕННЯ ДЛЯ УКРАЇНИ
Matrenitsky, V. L. (2022) · Likarska sprava · doi:10.31640/2706-8803-2022-(3-4)-04 · Cited by 1
Classical psychedelics in psychiatry – renaissance of interest and therapeutic perspectives
Jachimowski, A., & Kucia, K. A. (2023) · Psychiatria Polska · doi:10.12740/pp/150053
“Dostępne strategie terapeutyczne wydają się niewystarczające, a rozwój nowych leków w psychiatrii od pewnego czasu uległ wyhamowaniu [37].”
Recent Advances in Blood Brain Barrier on Chip ModelsPreprint
Vetter, J., Palagi, I., Waisman, A., & Blaeser, A. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.5047806
Phenotypic Polypharmacology Drug Discovery for CNS Applications
Ambesi‐Impiombato, A., McDermott, L. A., Pehrson, A. L., & Brunner, D. (2024) · Wiley eBooks · doi:10.1002/9781394182862.ch19
The Conundrums in Behavioral Animal Research and Some Findings with Ketamine
Ventura-Aquino, E., & Ågmo, A. (2025) · Neuromethods · doi:10.1007/978-1-0716-4603-8_4
Reflections on Reductionist Clinical Psychological and Neuroscience Education: Putting the “Me” Back in Mental Disorders
Ney, L. J. (2026) · Wiley Interdisciplinary Reviews Cognitive Science · doi:10.1002/wcs.70021 · Cited by 1
Psilocin fosters neuroplasticity in iPSC-derived human cortical neuronsPreprint
Schmidt, M., Hoffrichter, A., Davoudi, M., Horschitz, S., Lau, T., Meinhardt, M. W., Spanagel, R., Ladewig, J., Köhr, G., & Koch, P. J. (2026) · eLife · doi:10.7554/elife.104006.2
Evaluating the Translation Value of Two In Vivo Models for Breast Cancer Brain Metastases
Cold, S., Alfsen, M. Z., Halgirsson, B., et al. (2026) · Cancers · doi:10.3390/cancers18071095
“Drugs targeting intracranial tumours or metastases have proven especially challenging, with very low success rates [10–12].”
Psilocin fosters neuroplasticity in iPSC-derived human cortical neurons
Schmidt, M., Hoffrichter, A., Davoudi, M., Horschitz, S., Lau, T., Meinhardt, M. W., Spanagel, R., Ladewig, J., Köhr, G., & Koch, P. (2026) · eLife · doi:10.7554/elife.104006.3 · Cited by 9
Changement de paradigme dans l’innovation pharmaceutique et la distribution officinale : analyse comparative des droits français, allemand et suisse
Cramer, L. (2020) · doi:10.70675/8ba5d59ez2ec1z49daz8029z8accdd6aadf3
Neuroimaging and epigenetic machine-learning analyses to predict conversion to psychosis : towards a neurodevelopmental model
Iftimovici, A. (2021) · theses.fr (ABES) · doi:10.70675/66dc1447zdec5z4e5dz9972zfe7cd0a1f9bb
Polymeric nanoparticles functionalized with peptides: Advanced strategies for crossing the blood–brain barrier
Llorente, X., Esteruelas, G., García, M. B. G., Souto, E. B., & Sánchez-López, E. (. (2026) · Advances in pharmacology · doi:10.1016/bs.apha.2026.03.002
SpiraMed – A Stereotactic Helix-based Therapy Delivery system for the Human BrainPreprint
Bulstrode, H. J. C. J., Young, A., Huysman, I., Seevaratnam, D., Man, K. K., Pak, H. L., Wilson, G., Stamper, A., Wang, X., Wang, Y., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.09.27.754823
“The blood-brain barrier prevents or compromises systemic delivery of many agents 2 , with overall just 8% of candidate CNS therapies succeeding in clinical trials 3,4 .”
Cell-Based Therapeutics in Stroke: An Industry Perspective
Bednar, M. M. (2015) · Springer eBooks · doi:10.1007/978-3-319-15063-5_2
“Perhaps not surprisingly, many major pharmaceutical companies began to deemphasize neuroscience as a therapeutic area [6], although the most consistent failures have come in the attempts to treat acute neurologic disease such as stroke and traumatic brain injury (TBI).”
Background

Authors: Miller, G.
Corresponding author: Miller, Greg
Venue: Science
Publisher: American Association for the Advancement of Science (AAAS)
Published: 2010-07-30
Volume: 329
Issue: 5991
Pages: 502-504
ISSN: 0036-8075 (ISSN-L)
1095-9203
DOI: 10.1126/science.329.5991.502
OpenAlex: W2075757880
Cited by: 284
References: 0
Citations by year: 2026: 8 · 2025: 9 · 2024: 13 · 2023: 11 · 2022: 24 · 2021: 14 · 2020: 12 · 2019: 23 · 2018: 15 · 2017: 25 · 2016: 11 · 2015: 25 · 2014: 18 · 2013: 21 · 2012: 31
Type: other
Language: en
Open access: closed
Locations: Science (publishedVersion)
PubMed (publishedVersion)
Topics: Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
Health Sciences › Nursing › Issues, ethics and legal aspects › Pharmaceutical industry and healthcare
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Keywords: drug development, neurological disorders, pharmaceutical industry, research funding cuts, brain research, neuropharmacology
MeSH terms: Mental Disorders, Central Nervous System Agents, Central Nervous System Diseases, Clinical Trials as Topic, Drug Industry, Humans, Drug Approval, Access to Information, Biomedical Research, Drug Discovery, Public-Private Sector Partnerships

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Is Pharma Running Out of Brainy Ideas?

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cited by

Related

Metadata

Record

About these checks